MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
VSTM stock logo

VSTM

Verastem, Inc.

$5.75
-0.28
 (-4.64%)
Exchange:  NASDAQ
Market Cap:  398.555M
Shares Outstanding:  12.777M
Delayed data
Calculate VSTM Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Daniel W. Paterson
Full Time Employees:  102
Address: 
117 Kendrick Street
Needham
MA
2494
US
Website:  https://www.verastem.com
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a “clamp” mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF’s ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer’s FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen’s KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/08/08 — Q2 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue010,00030,914
Gross Profit010,00025,616
EBITDA-83,166-125,864-207,605
Operating Income-92,084-114,956-170,129
Net Income-87,367-130,637-209,471

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets149,718101,538246,442
Total Liabilities92,344130,431189,245
Total Stockholders Equity57,374-28,89357,197
Total Debt41,55742,25476,865
Cash and Cash Equivalents78,83588,818204,990

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-86,460-104,771-137,509
Capital Expenditure7-280
Free Cash Flow-86,460-104,799-137,509
Net Income-87,367-130,637-209,471
Net Change in Cash3,2879,983116,172

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)537,339.865Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)607,358.305Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)573,062.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-364,414.983Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-322,403.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-343,837.399Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)37,259.825Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)43,700.018Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)40,545.765Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)3,154,603.059Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,565,665.776Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)3,364,321.738Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.590Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.630Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.540Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)7Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
8.43
?Net Income
 (TTM)
: 
-87367000  ?P/E
 (TTM)
: 
-2.41
?Enterprise Value
 (TTM)
: 
337.887M  ?EV/FCF
 (TTM)
: 
-2.22
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-486.41%  ?ROIC
 (TTM)
: 
-102.15%
?Net Debt
 (TTM)
: 
-71986000  ?Debt/Equity
 (TTM)
: 
1.05
?P/B
 (TTM)
: 
7.25  ?Current Ratio
 (TTM)
: 
3.04

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about VSTM valuation

Is Verastem, Inc. (VSTM) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Verastem, Inc. (VSTM) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is VSTM a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VSTM trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is VSTM’s P/E ratio?

You can see VSTM’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for VSTM?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is VSTM a good long-term investment?

Whether VSTM fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

VSTM

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.64
MARKETSnap

Trading Metrics:

Open: 6.03   Previous Close: 6.03
Day Low: 5.71   Day High: 6.22
Year Low: 3.43   Year High: 11.25
Price Avg 50: 4.45   Price Avg 200: 6.59
Volume: 2.519M   Average Volume: 2.62M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026 16:05
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
23-06-2026 20:32
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
17-06-2026 12:45
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
15-06-2026 16:01
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
07-05-2026 23:41
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts
24-04-2026 02:31
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read